Astellas Pharma Inc.

About

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company listed on the Tokyo Stock Exchange (ticker 4503). It was formed in 2005 from the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical and is headquartered in the Nihonbashi-Honcho district of Chuo-ku, Tokyo. It is included here as a major industry player whose portfolio intersects with aging biology rather than as a dedicated longevity company. Several of its designated Primary Focus areas bear on age-related disease. Through the Astellas Institute for Regenerative Medicine, its cell therapy ASP7317 delivers human-embryonic-stem-cell-derived retinal pigment epithelial cells to older patients with advanced dry age-related macular degeneration (geographic atrophy), with preliminary Phase 1b data reported at ARVO 2026. Its Mitochondria Biology focus, built through the acquisition of Mitobridge and a collaboration with Minovia Therapeutics, pursues therapies targeting mitochondrial dysfunction, a recognised hallmark of aging. Research and development is led by the Chief Research and Development Officer.

Rating breakdown

Aggregate 49/100 · rank #6 in the commercial table full ratings →

Expand a signal to see what contributes to it.

Key outputs

• drug candidate ASP7317: human-embryonic-stem-cell-derived retinal pigment epithelial cell therapy (subretinal) in a Phase 1b study for geographic atrophy secondary to dry age-related macular degeneration; ARVO 2026 preliminary data showed best-corrected visual-acuity gains across dose cohorts at 26 weeks (NCT03178149; Astellas Institute for Regenerative Medicine) ↗ 2026
• other Mitochondria Biology Primary Focus: capability built through the acquisition of Mitobridge (mitochondrial dysfunction, a hallmark of aging) and expanded via a mitochondrial cell-therapy collaboration with Minovia Therapeutics ↗ 2021

Registered clinical trials

104 trials list this organisation as lead sponsor ClinicalTrials.gov ↗

• Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer ↗ PHASE1, PHASE2 · RECRUITING · 2026-03-11
• DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma ↗ PHASE2 · RECRUITING · 2025-12-16
• Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators ↗ PHASE1, PHASE2 · RECRUITING · 2025-12-15
• FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy ↗ PHASE2 · RECRUITING · 2025-12-05
• Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria ↗ RECRUITING · 2025-07-21
• A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy ↗ ACTIVE_NOT_RECRUITING · 2025-01-22
• Relugolix + Enzalutamide Study in High-Risk Prostate Cancer ↗ PHASE1 · RECRUITING · 2024-12-26
• Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients ↗ COMPLETED · 2024-07-10

Showing 8 of 104 registered trials.

Financial

Market cap

JPY 4110.00B · 4503 (2026-09-29)

Recent deals & partnerships

Headline values are potential totals (mostly contingent milestones), not cash received.

Key people

Research fields

Links